http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-980227-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_232361c9031a709144573276863c462b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-555 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-555 |
| filingDate | 1962-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7373d70a914dfbb050936c49e94c8b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_738968c244c2625ee3bcf22db34af243 |
| publicationDate | 1965-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-980227-A |
| titleOfInvention | Purification and/or concentration of material containing interferon |
| abstract | A material containing interferon is purified and/or concentrated by adsorbing the crude interferon at a pH less than 6 from an aqueous medium on to one or more alumino-silicate adsorbents having a high molar ratio of SiO2 to Al2O3, e.g. greater than 5 and preferably a particle size below 50 microns and subsequently eluting the interferon therefrom by means of an aqueous solution of an electrolyte at a pH greater than 5.5 For batch operation, the particle size of the alumino-silicate should be below 50, and preferably below 25, microns. The alumino-silicate is preferably synthetic and should contain a proportion of alkali metal oxide, e.g. sodium oxide, in combined form in the ratio to alumina of 1 : 3 to 3 : 1. Adsorption is at pH 2 to 6 and, at pH above 5.0, the ionic concentration of the interferon solution should be not greatly in excess of isotonic. Elution is preferably carried out at a pH not less than 6.0. Aqueous solutions of buffers, e.g. disodium or dipotassium hydrogen phosphate of pH 7.5 and aqueous solutions of ammonium formate alkali metal and alkaline earth metal hydroxides, carbonates and bicarbonates, may be used. The interferon may be recovered by freeze-drying the eluate or by adding a volatile precipitant such as a water-miscible alcohol or ketone to the eluate. The interferon may be produced by treating avian cells such as egg chlorio allantoic cells or whole chick embryos or mammalian cells such as monkey kidney or human amnion cells with influenza virus, Newcastle disease or fowl plague. |
| priorityDate | 1962-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.